FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP						
	STATEMENT	OF CHA	ANGES IN	I BENEFICI <i>A</i>	AL OWI	NERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cagle Gerald D.			2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [CLSD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
Cagle Gerald D.												X	Directo	r		10% Ov	vner		
(Last)	`	irst) BIOMEDICAL, l	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/20/2018								Officer (give title below)			Other (s below)	specify		
900 NORTH POINT PARKWAY, SUITE 200			4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) ALPHAI	RETTA G	A	30005										X						
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		Code (I	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			and Securitie Beneficia		es Formally (D) (Following (I) (I		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
						Code	v	Amount	(A) oi (D)	Pr	ice	Transact (Instr. 3 a	ion(s)			(511 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		Co	Fransaction of Code (Instr. Derivati		ve es d ed nstr.	Expiration Date (Month/Day/Year)		1	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$10.74	06/20/2018			A		11,250		(1)	0	06/19/2028	Common Stock	11,2	250	\$0.00	11,250)	D	

Explanation of Responses:

1. The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019.

Remarks:

/s/ Brian F. Leaf, Attorney-in-Fact 06/21/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.